Related Experiment Video
Updated: Feb 16, 2026

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells
Tulin Ozkan1, Yalda Hekmatshoar1, Tugba Ertan-Bolelli2
1Department of Medical Biology, School of Medicine, Ankara University, Ankara, Turkey.
Background:
The tyrosine kinase inhibitor, imatinib, used as a first line treatment in Chronic Myeloid Leukemia (CML) patients, may lead to resistance and failure to therapy. Novel combinations of imatinib with other drugs is a strategy to improve treatment efficiency.
Objective:
In this study, the antileukemic and apoptotic effects of a benzamide derivative XT5 and benzoxazole derivative XT2B and their combination with imatinib were investigated in imatinib-sensitive (K562S) and imatinib-resistant (K562R) CML cells.
Methods:
In vitro cytotoxicity was determined by MTT assay. Then, apoptotic effect of XT5 on CML cell lines was tested by Annexin V flow cytometry, caspase activation and RT-PCR. Docking calculation was performed using AutoDock Vina in PyMOL environment using AutoDock/Vina plugin for PyMOL.
Results:
According to our MTT assay data, XT5 indicated significant antiproliferative effect on cell lines, therefore we investigated apoptotic effects of XT5. Treatment of K562 cell lines with a combination of XT5 and imatinib-XT5 increased cytotoxicity, the Annexin V binding and caspase 3/7 activation. In addition to apoptosis assays, we observed an increase in the expression levels of the pro-apoptotic (BAX, BAD and BIM) genes in XT5 treated K562R and K562S cells. Molecular modelling experiments showed that XT5 showed hydrogenbonding interactions with important amino acids of BCR-ABL kinase receptor; however XT2B did not show any hydrogen bond interaction.
Conclusion:
Our results indicate that XT5 could be a potential candidate to be used as a new anticancer drug and XT5 combination with imatinib as an alternate treatment strategy for overcoming imatinib resistance.
Insights
The novel compound XT5 shows significant anticancer effects and enhances imatinib efficacy in Chronic Myeloid Leukemia (CML) cells. This combination therapy offers a promising strategy to overcome imatinib resistance in CML patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Imatinib is a first-line treatment for Chronic Myeloid Leukemia (CML).
- Therapy failure and resistance to imatinib are significant clinical challenges.
- Novel drug combinations are being explored to improve CML treatment outcomes.
Purpose of the Study:
- To investigate the antileukemic and apoptotic effects of XT5 and XT2B, alone and in combination with imatinib.
- To evaluate these effects in both imatinib-sensitive (K562S) and imatinib-resistant (K562R) CML cell lines.
- To explore the potential of XT5 as a new anticancer agent and combination therapy for CML.
Main Methods:
- In vitro cytotoxicity assessed using MTT assay.
- Apoptotic effects evaluated via Annexin V flow cytometry, caspase activation assays, and RT-PCR.
- Molecular docking studies performed using AutoDock Vina to analyze drug-target interactions.
Main Results:
- XT5 demonstrated significant antiproliferative and pro-apoptotic effects on CML cell lines.
- Combination of XT5 with imatinib enhanced cytotoxicity and apoptosis induction (Annexin V binding, caspase 3/7 activation).
- XT5 treatment increased the expression of pro-apoptotic genes (BAX, BAD, BIM) and showed favorable molecular interactions with the BCR-ABL kinase receptor.
Conclusions:
- XT5 is a potential candidate for a new anticancer drug.
- Combining XT5 with imatinib represents a viable strategy to overcome imatinib resistance in CML.
- Further research into XT5 and its combinations is warranted for CML treatment.
More Related Videos
08:59Live Imaging of Apoptotic Cell Clearance during Drosophila Embryogenesis
Published on: August 18, 2013
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
Related Concept Videos
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Rate-Determining Steps
In a multistep reaction mechanism, one of the elementary steps progresses significantly slower than the others. This slowest step is called the rate-limiting step (or rate-determining step). A reaction cannot proceed faster than its slowest step, and hence, the rate-determining step limits the overall reaction rate.
The concept of rate-determining step can be understood from the analogy of a 4-lane freeway with a short-stretch of traffic-bottleneck caused due to...
Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy
Real Gases: Effects of Intermolecular Forces and Molecular Volume Deriving Van der Waals Equation